19 Wednesday, September  2017 18:00

genetic PCR solutions™ launches new Assay Kit designed for detection Candida auris by qPCR. 30 years of experience on microbial phylogenetic diversity and taxonomy, together with demonstrated skills in design and validation, ensures the best possible real-time PCR assay following thestrictest criteria .

Candida auris is an emerging fungus which grows as yeast and one of the few Candida species which can cause candidiasis in humans. Healthcare facilities in several countries have reported that C. auris has caused severe illness in hospitalized patients with weakened immune systems. It can cause invasive candidiasis, in which the blood stream is invaded, the central nervous system, kidneys, liver, bones, muscles, joints, spleen, or eyes. Some strains of C. auris are resistant to all three major classes of antifungal drugs. This type of multidrug resistance has not been seen before in other species of Candida. For this reason treatment is complicated, because C. auris is easily misidentified as other Candidaspecies.                                       CanAur2

 

 

 

2 Monday, June  2017 14:30

VII International Conference on Environmental, Industrial and Applied Microbiology "from 18 to 20 October in Madrid (Spain), genetic PCR solutions™ will present" Advanced qPCR innovations and Validation for microbial testing in water and food "18 Thursday, May  2017 16:00

 

Biomicroworld

 

 The laboratory Genetic PCR SolutionsTM (GPSTM) has developed a new, “highly inclusive” RT-qPCR kit for rapid genetic detection of Zika virus.ç

 

Last Friday 19th, laboratories GPSTM from the company Genetic Analysis Strategies S.L. has launched a new RT-qPCR kit that allows Zika virus genetic detection in any sample. The GPSTM kit is already available worldwide. The test is more inclusive, all reagents are stable at room Tª and served in a MONODOSE format that minimize handling.

Recently, Zika virus disease – an emerging viral disease transmitted by Aedes mosquito bites - has been spreading in the Americas and the Caribbean, following the first cases reported in Brazil. Arrival of the virus has been associated with a steep increase in the birth of babies with abnormally small heads and in cases of Guillain-Barré syndrome. A causal relationship between Zika virus infection and birth defects and neurological syndromes has not been established, but is strongly suspected. As the spread of Zika virus disease continues in the American Region, the risk of Zika-infected travellers entering Europe increases. Imported cases of Zika virus infection have been reported in several European countries.

Zika la Verdad

On 1st February 2016, the World Health Organisation (WHO) declared the Zika Virus outbreak to be a Public Health Emergency of International Concern.

A report dated on 29th January from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC, indicated: There is no commercially available test for Zika virus” and “serologic assays can be positive because of cross-reacting antibodies against related flaviviruses“.

In a few weeks, scientists from GPSTM have designed new specific primers and probes to detect the Zika virus, taking into account all new genomic sequences deposited to date at the public database (NCBI). As a consequence, the specificity of the test (in particular the inclusivity) has been improved in relation to these published to date in international journals. Calibration may be achieved with the standard known-copy number (included), to be used for estimative quantification.  The kit is available at several rxn-formats (F100, F300), but also in MONODOSE M60 and M120.